In a report issued on May 2, Roanna Ruiz from SVB Securities maintained a Buy rating on Pardes Biosciences (PRDS – Research Report). The company’s shares closed last Tuesday at $7.47, close to its 52-week low of $5.54.
According to TipRanks.com, Ruiz has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -27.3% and a 25.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Xeris Pharmaceuticals, and Atea Pharmaceuticals.
Currently, the analyst consensus on Pardes Biosciences is a Moderate Buy with an average price target of $25.00, which is a 228.9% upside from current levels. In a report issued on May 1, Jefferies also maintained a Buy rating on the stock with a $25.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
FS Development Corp II is a blank check company.
Read More on PRDS: